Amylyx Pharmaceuticals (AMLX) Gross Margin (2022 - 2024)

Amylyx Pharmaceuticals has reported Gross Margin for 3 years, with the latest figure at 100.0% in Q4 2024.

• On a quarterly basis, Gross Margin rose 863.0% year-over-year to 100.0% in Q4 2024; TTM through Sep 2025 was 100.0%, a 771.0% increase from a year earlier, with the FY2024 full-year figure at 93.19%, down 13.0% from the prior year.
• Gross Margin was 100.0% for Q4 2024 at Amylyx Pharmaceuticals, roughly flat from 100.0% in the prior quarter.
• The five-year high for Gross Margin was 100.0% in Q3 2024, with the low at 50.14% in Q3 2022.
• Average Gross Margin over 3 years is 90.3%, with a median of 93.81% recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Gross Margin jumped 4477 bps in 2023, then surged 69 bps in 2024.
• Over 3 years, Gross Margin stood at 87.11% in 2022, then climbed by 5 bps to 91.37% in 2023, then grew by 9 bps to 100.0% in 2024.
• The last three Gross Margin figures came in at 100.0% (Q4 2024), 100.0% (Q3 2024), and 99.22% (Q2 2024), per Business Quant data.